MDR1-P-glycoprotein (ABCB1) mediates transport of Alzheimer's amyloid-β peptides - Implications for the mechanisms of Aβ clearance at the blood-brain barrier

Brain Pathology

Volumn 17, Issue 4, 2007, Pages 347-353

  Kuhnke, Diana ^a   Jedlitschky, Gabriele ^a   Grube, Markus ^a   Krohn, Markus ^b   Jucker, Mathias ^c   Mosyagin, Igor ^d   Cascorbi, Ingolf ^d   Walker, Lary C ^e   Kroemer, Heyo K ^a   Warzok, Rolf W ^b   Vogelgesang, Silke ^b  

^a Research Center of Pharmacology and Experimental Therapeutics   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; FLUORESCEIN ISOTHIOCYANATE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; RHODAMINE 123;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; BLOOD BRAIN BARRIER; CELL CULTURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR SPACE; FLUORESCENCE ANALYSIS; FUNCTIONAL PROTEOMICS; GENETIC TRANSFECTION; MEMBRANE VESICLE; NEUROBIOLOGY; NONHUMAN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT;

EID: 35148859731     PISSN: 10156305     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2007.00075.x     Document Type: Article

References (32)

1. Ambudkar SV, Kim IW, Sauna ZE (2005) The power of the pump: mechanisms of action of P-glycoprotein (ABCB1). Eur J Pharm Sci 580 : 1049 1055.
2. Bendayan R, Lee G, Bendayan M (2002) Functional expression and localization of P-glycoprotein at the blood brain barrier. Microsc Res Tech 57 : 365 380.
3. Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, Jiang H, Prior JL, Sagare A, Bales KR, Paul SM, Zlokovic BV, Piwnica-Worms D, Holtzman DM (2005) P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest 115 : 3285 3290.
4. Cummings J (2004) Alzheimer's disease. N Engl J Med 351 : 56 67.
5. Deane R, Wu Z, Zlokovic BV (2004) RAGE (yin) versus LRP (yang) balance regulates Alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke 35 (11 Suppl. 1 2628 2631.
6. Drozdzik M, Bialecka M, Mysliwiec K, Honczarenko K, Stankiewicz J, Sych Z (2003) Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics 13 : 259 263.
7. Furuno T, Landi MT, Ceroni M, Caporaso N, Bernucci I, Nappi G, Martignoni E, Schaeffeler E, Eichelbaum M, Schwab M, Zanger UM (2002) Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics 12 : 529 534.
8. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2 : 48 58.
9. Izzo AA (2005) Herb-drug interactions: an overview of the clinical evidence. Fundam Clin Pharmacol 19 : 1 16.
10. Johne A, Brockmoeller J, Bauer S, Maurer A, Langheinrich M, Roots I (1999) Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther 66 : 338 345.
11. Keppler D, Jedlitschky G, Leier I (1998) Transport function and substrate specificity of multidrug resistance protein. Methods Enzymol 292 : 607 616.
12. Lam FC, Liu R, Lu P, Shapiro AB, Renoir JM, Sharom FJ, Reiner PB (2001) beta-Amyloid efflux mediated by p-glycoprotein. J Neurochem 76 : 1121 1128.
13. Lee G, Schlichter L, Bendayan M, Bendayan R (2001) Functional expression of P-glycoprotein in rat brain microglia. J Pharmacol Exp Ther 299 : 204 212.
14. LeVine H 3rd (1999) Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol 309 : 274 284.
15. Loeb MB, Molloy DW, Smieja M, Standish T, Goldsmith CH, Mahony J, Smith S, Borrie M, Decoteau E, Davidson W, McDougall A, Gnarpe J, O'Donnell M, Chernesky M (2004) A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease. J Am Geriatr Soc 52 : 381 387.
16. Rajagopal A, Simon SM (2003) Subcellular localization and activity of multidrug resistance proteins. Mol Biol Cell 14 : 3389 3399.
17. Rautio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, Kunta JR, Serabjit-Singh CJ, Polli JW (2006) In vitro P-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos 34 : 786 792.
18. Revesz T, Holton JL, Lashley T, Plant G, Rostagno A, Ghiso J, Frangione B (2002) Sporadic and familial cerebral amyloid angiopathies. Brain Pathol 12 : 343 357.
19. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, Van DeemTer L, Mol CA, Van der Valk MA, Robanus-Maandag EC, Te Riele HP, Berns AJM, Borst P (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77 : 491 502.
20. Schlachetzki F, Pardridge WM (2003) P-glycoprotein and caveolin-1alpha in endothelium and astrocytes of primate brain. Neuroreport 14 : 2041 2046.
21. Selkoe DJ (1999) Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399 : A23 A31.
22. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV (2000) Clearance of Alzheimer's amyloid-ß 1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106 : 1489 1499.
23. Smyth MJ, Krasovskis E, Sutton VR, Johnstone RW (1998) The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci USA 95 : 7024 7029.
24. Tainton KM, Smyth MJ, Jackson JT, Tanner JE, Cerruti L, Jane SM, Darcy PK, Johnstone RW (2004) Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux. Cell Death Differ 11 : 1028 1037.
25. Vinters VH (1987) Cerebral amyloid angiopathy: a critical review. Stroke 18 : 311 324.
26. Vogelgesang S, Cascorbi I, Schroeder E, Pahnke J, Kroemer HK, Siegmund W, Kunert-Keil C, Walker LC, Warzok RW (2002) Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 12 : 535 541.
27. Vogelgesang S, Warzok RW, Cascorbi I, Kunert-Keil C, Schroeder E, Kroemer HK, Siegmund W, Walker LC, Pahnke J (2004) The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease. Curr Alzheimer Res 1 : 121 125.
28. Volk HA, Burkhardt K, Potschka H, Chen J, Becker A, Loscher W (2004) Neuronal expression of the drug efflux transporter P-glycoprotein in the rat hippocampus after limbic seizures. Neuroscience 123 : 751 759.
29. Volk H, Potschka H, Loscher W (2005) Immunohistochemical localization of P-glycoprotein in rat brain and detection of its increased expression by seizures are sensitive to fixation and staining variables. J Histochem Cytochem 53 : 517 531.
30. Westphal K, Weinbrenner A, Gießmann T, Stuhr M, Franke G, Zschiesche M, Oertel R, Terhaag B, Kroemer HK, Siegmund W (2000) Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther 68 : 6 12.
31. Zlokovic BV, Yamada S, Holtzman D, Ghiso J, Frangione B (2000) Clearance of amyloid beta-peptide from brain: transport or metabolism? Nat Med 6 : 718 719.
32. Zlokovic BV, Deane R, Sallstrom J, Chow N, Miano JM (2005) Neurovascular pathways and Alzheimer amyloid beta-peptide. Brain Pathol 15 : 78 83.